chronic myelogenous leukemia
Quick Summary
Chronic myelogenous leukemia (CML) is a type of cancer affecting the blood-forming tissues, specifically characterized by an overproduction of immature white blood cells. It is classified as a chronic leukemia, meaning it develops gradually and can persist for extended periods.12
CML is strongly associated with a specific genetic abnormality known as the Philadelphia chromosome. This occurs when a segment of chromosome 9 fuses with a segment of chromosome 22, creating a hybrid gene called BCR-ABL. This abnormal gene produces a protein that disrupts normal cell growth regulation, leading to the uncontrolled proliferation of leukemic cells.23
While CML can remain dormant for a long time, symptoms like weight loss, fever, and weakness may eventually appear. Without treatment, it can progress to a fatal stage called blast crisis. The average lifespan for individuals with CML has historically been around 3 years, though many can live for 5 to 10 years or longer with treatment.12
Ask Britannica AI about this topic
Britannica doesn't have a full article on this topic, so we've curated a list of our relevant coverage.
blood diseaseLeukemiaChronic myelogenous leukemia (CML) is characterized by the appearance in the blood of large numbers of immature white blood cells of the myelogenous series in the stage following the myeloblast, namely, myelocytes. The spleen becomes enlarged, anemia develops, and the affected person may lose weight.…
Read MoreChronic myelogenous leukemia (CML) is characterized by the appearance in the blood of large numbers of immature white blood cells of the myelogenous series in the stage following the myeloblast, namely, myelocytes. The spleen becomes enlarged, anemia develops, and the affected person may lose weight.…
Read More- blood diseaseLeukemia
Chronic myelogenous leukemia is treated with the drugs hydroxyurea or busulfan in daily doses until the leukocyte count has returned to normal. Treatment then is interrupted until the leukocyte count has risen to about 50,000 cells per cubic millimetre, when treatment is resumed. This can…
Read MoreChronic myelogenous leukemia is treated with the drugs hydroxyurea or busulfan in daily doses until the leukocyte count has returned to normal. Treatment then is interrupted until the leukocyte count has risen to about 50,000 cells per cubic millimetre, when treatment is resumed. This can…
Read More
cancerTargeted therapies…abnormal protein present only in chronic myelogenous leukemia (CML) cells, imatinib can control CML without causing extensive disturbance in normal cells. Gastrointestinal stromal tumors (GISTs), which are unrelated to CML and originate from a different cell type, possess a mutated protein with a similar function to the one targeted by…
Read More…abnormal protein present only in chronic myelogenous leukemia (CML) cells, imatinib can control CML without causing extensive disturbance in normal cells. Gastrointestinal stromal tumors (GISTs), which are unrelated to CML and originate from a different cell type, possess a mutated protein with a similar function to the one targeted by…
Read More
kinase…of human leukemia, CML (chronic myelogenous leukemia), is caused by excess activity of the Abelson tyrosine kinase. Imatinib (Gleevec) is a chemical that binds to the active site of this kinase, thereby blocking the enzyme’s ability to phosphorylate targets. Imatinib has been useful in the initial treatment of CML;…
Read More…of human leukemia, CML (chronic myelogenous leukemia), is caused by excess activity of the Abelson tyrosine kinase. Imatinib (Gleevec) is a chemical that binds to the active site of this kinase, thereby blocking the enzyme’s ability to phosphorylate targets. Imatinib has been useful in the initial treatment of CML;…
Read More
imatinib…of chronic myelogenous leukemia (CML). Imatinib was approved by the U.S. Food and Drug Administration in 2001 under the trade name Gleevec for the treatment of CML. The following year it was approved for the treatment of advanced gastrointestinal stromal tumours (GISTs), which are rare cancers affecting interstitial cells…
Read More…of chronic myelogenous leukemia (CML). Imatinib was approved by the U.S. Food and Drug Administration in 2001 under the trade name Gleevec for the treatment of CML. The following year it was approved for the treatment of advanced gastrointestinal stromal tumours (GISTs), which are rare cancers affecting interstitial cells…
Read More